INTRODUCTION: Atrial fibrillation (AF) is one of the main risk factors for stroke. Vitamin K antagonists (VKA) reduce this risk, and the effectiveness of this treatment is directly related to time in therapeutic range (TTR). This study aimed to report the TTR in patients with non-valvular AF at an anticoagulation outpatient clinic; and to describe the profile of this population of patients in terms of risk of stroke, as well a
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke...
Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well kn...
Strokes and transient ischaemic attacks in patients with atrial fibrillation (AF) can be largely pre...
INTRODUCTION: Atrial fibrillation (AF) is one of the main risk factors for stroke. Vitamin K antagon...
Despite vitamin K antagonists (VKAs) are considered the first choice treatment for stroke prevention...
Background: Vitamin K antagonists (VKAs) reduce cardiovascular events (CVEs) in atrial fibrillation ...
AbstractPurposePatients with atrial fibrillation are at increased risk for stroke and thus require a...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Atrial fibrillation is the world's most common sustained cardiac arrhythmia and is associated with a...
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a tar...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for p...
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke...
Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well kn...
Strokes and transient ischaemic attacks in patients with atrial fibrillation (AF) can be largely pre...
INTRODUCTION: Atrial fibrillation (AF) is one of the main risk factors for stroke. Vitamin K antagon...
Despite vitamin K antagonists (VKAs) are considered the first choice treatment for stroke prevention...
Background: Vitamin K antagonists (VKAs) reduce cardiovascular events (CVEs) in atrial fibrillation ...
AbstractPurposePatients with atrial fibrillation are at increased risk for stroke and thus require a...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Atrial fibrillation is the world's most common sustained cardiac arrhythmia and is associated with a...
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a tar...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for p...
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke...
Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well kn...
Strokes and transient ischaemic attacks in patients with atrial fibrillation (AF) can be largely pre...